Official title: An Open-Label, Multi-center Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations Summary: The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations. Conditions: Solid Tumors With FGFR2 Alterations, Adult Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE1, PHASE2 Enrollment: 130 (ESTIMATED) Status: RECRUITING Completion: 2028-06-16 (ESTIMATED)
ClinicalTrials.gov published a clinical update in Oncology on 27 Jan 2026.
The item focuses on A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations.
Review the original article for the full source wording and details.